about
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersPegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCombination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairLung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerEvaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaA Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast CancerPatient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical CancerSargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced MelanomaCombination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by SurgeryPaclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by SurgeryCarboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryDigital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast CancerDocetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast CancerChemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerS0820, Adenoma and Second Primary Prevention TrialS1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast CancerRadiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal CancerOlaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial CancerMelphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaRadiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take CisplatinOlanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic ChemotherapyRadiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and EtoposideDocetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerSorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver CancerLung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesFulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-PositiveChemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By SurgeryCarboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
P6153
Q58407878-CFBD9B76-ECD2-4F46-A415-0BDC90AFF49BQ58845627-3731FB64-33B6-486B-A274-4541FE78B35AQ58845885-E783D6E6-5724-40F3-883A-C8D7362D4B4DQ61865593-311523D9-3592-41FB-990D-D52262D148C0Q61906994-50303074-4F22-43E0-B911-0C4B8FFE95B9Q61921666-FB425CCB-5118-49B7-9B76-B1394F40A12CQ61936011-09F5166C-6B37-49DB-802C-38BDCD497699Q61936299-9AF558B5-9C47-4933-8CE0-9F6AD0B004D8Q61970163-2ECCEF0C-04DD-4825-B067-D018EE06924DQ61978971-9060BC5E-2785-43D8-85C8-49DBAACAC160Q61981377-31D5A9D6-0E69-4C60-A3B4-2C92C90A55B2Q62105307-7D7A0C5C-0B0B-4379-B9D7-F4000A53759BQ63011965-D4094AB2-D51A-4FF7-A945-96FCB9028CD8Q63316568-197EFD2C-2A42-4302-B1C9-6EE28E6ABBC8Q63333649-983C5BB4-7A49-468B-BF85-69C6CAC713A4Q63335032-408FA47D-DC2B-4967-8FFF-A64392CA5817Q63404059-170C7FB7-5B52-4A04-A026-AA9E0B66DBFEQ63571364-3DE299B0-173B-416B-90AC-DB94B55E8FFFQ63571541-AD323347-A6ED-4FBC-81DD-9F3B4013B4F9Q63571770-E3BB78A0-9A26-42CF-AE46-3E6733633F0DQ63572857-18A17FE6-B856-44C6-BDCE-1B580A72694AQ63573996-B3127350-574B-4F0D-95F3-27A284D329ADQ64123696-783580C2-BDC9-43C7-8A94-4895AA9894D7Q64150460-EC367758-2633-48C1-8D38-7476E4E6DDEBQ64150545-9E8EF717-A190-4285-8902-1B31D50EEC9FQ64151321-16879A97-DBDF-43E3-B804-0B81082A3B4CQ64170973-986FBF2B-5A4B-4A74-81C4-2A57B30516E2Q64171079-01A558D1-F381-41ED-B78F-FC59F87A6A10Q64173499-F5EE58D4-396C-46DC-BA45-855414CD7151
P6153
description
amerikanische Non-Profit-Organisation
@de
nonprofit organization in Canton, United States
@en
name
Aultman Health Foundation
@en
type
label
Aultman Health Foundation
@en
prefLabel
Aultman Health Foundation
@en
P131
P213
0000 0004 4655 7357
P2427
grid.414073.5
P571
1984-01-01T00:00:00Z
P625
Point (-81.504335 40.822173)